Fortrea (NASDAQ:FTRE) Stock Price Breaks Below 50 Day Moving Average on Analyst Downgrade

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) crossed below its 50 day moving average during trading on Wednesday after Mizuho downgraded the stock from a neutral rating to an underperform rating. The stock has a 50 day moving average of $20.70 and traded as low as $20.36. Mizuho now has a $19.00 price target on the stock, up from their previous price target of $16.00. Fortrea shares last traded at $20.38, with a volume of 1,518,189 shares changing hands.

Other research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fortrea in a report on Thursday, October 15th. Zacks Research lowered Fortrea from a “hold” rating to a “strong sell” rating in a research report on Monday, October 12th. William Blair raised Fortrea to a “hold” rating in a research note on Wednesday, July 29th. Jefferies Financial Group restated a “hold” rating and set a $21.50 price objective on shares of Fortrea in a research report on Friday, October 30th. Finally, Deutsche Bank upgraded Fortrea from a “hold” rating to a “buy” rating and raised their price objective for the stock from $20.00 to $25.00 in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Fortrea presently has a consensus rating of “Hold” and an average target price of $24.23.

View Our Latest Stock Report on FTRE

Institutional Investors Weigh In On Fortrea

Several large investors have recently modified their holdings of FTRE. WINTON GROUP Ltd lifted its holdings in Fortrea by 26.7% in the second quarter. WINTON GROUP Ltd now owns 389,155 shares of the company’s stock valued at $6,771,000 after buying an additional 82,059 shares during the period. Eagle Health Investments LP boosted its position in Fortrea by 7.3% during the first quarter. Eagle Health Investments LP now owns 1,307,560 shares of the company’s stock valued at $12,317,000 after acquiring an additional 89,000 shares during the last quarter. Wellington Management Group LLP bought a new stake in Fortrea during the second quarter valued at $41,488,000. Assenagon Asset Management S.A. boosted its position in Fortrea by 90.7% during the second quarter. Assenagon Asset Management S.A. now owns 173,129 shares of the company’s stock valued at $3,012,000 after acquiring an additional 82,349 shares during the last quarter. Finally, Pullen Investment Management LLC acquired a new stake in Fortrea during the 3rd quarter worth about $2,220,000.

Fortrea Stock Performance

The company has a debt-to-equity ratio of 1.94, a quick ratio of 0.97 and a current ratio of 0.97. The stock has a fifty day simple moving average of $20.73 and a two-hundred day simple moving average of $15.93. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -27.48, a P/E/G ratio of 0.51 and a beta of 1.88.

Fortrea (NASDAQ:FTRE – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.06. The firm had revenue of $691.50 million during the quarter, compared to analyst estimates of $671.57 million. Fortrea had a positive return on equity of 13.98% and a negative net margin of 2.58%. Analysts forecast that Fortrea Holdings Inc. will post 0.85 earnings per share for the current fiscal year.

Fortrea Company Profile

(Get Free Report)

Fortrea Holdings Inc. is a global contract research organization that provides clinical development and patient access services to pharmaceutical, biotechnology and medical device companies. The company supports the development of medicines and medical products from early research through later-stage clinical trials and post-approval studies. Its services include clinical trial planning and management, clinical pharmacology, patient recruitment and engagement, data management, regulatory support and related consulting.

Recommended Stories

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.